Terms: = Lung cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
904 results:
1. Beyond Chemoimmunotherapy in Advanced Non-Small Cell lung cancer: New Frontiers, New Challenges.
Mountzios G; Naidoo J; Wang C; Creelan BC; Trotier DC; Campbell TC; Peters S
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432526. PubMed ID: 38781566
[TBL] [Abstract] [Full Text] [Related]
2. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract] [Full Text] [Related]
3. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
4. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
5. The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
Malapelle U; Passiglia F; Pepe F; Pisapia P; Lucia Reale M; Cortinovis D; Fraggetta F; Galetta D; Garbo E; Graziano P; Pagni F; Pasello G; Piovano P; Pilotto S; Tiseo M; Genova C; Righi L; Troncone G; Novello S
Lung Cancer; 2024 May; 191():107787. PubMed ID: 38593479
[TBL] [Abstract] [Full Text] [Related]
6. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
7. Targeting ret alterations in non-small cell lung cancer.
Nishikawa G; Klein MA
Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
[TBL] [Abstract] [Full Text] [Related]
8. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, ret fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
9. Unraveling the Promise of ret Inhibitors in Precision cancer Therapy by Targeting ret Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract] [Full Text] [Related]
10. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with ret-rearranged nonsmall cell lung cancer.
Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
[TBL] [Abstract] [Full Text] [Related]
11. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell lung cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract] [Full Text] [Related]
12. [Intraductal carcinomas of the salivary glands: a clinicopathological and molecular genetic analysis of twenty-seven cases].
Sun Q; Sun JJ; Wang M; Zhang L; Zhang XW; Wei JG; Kong LF; Li J
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):250-256. PubMed ID: 38433052
[No Abstract] [Full Text] [Related]
13. Generating Potential ret-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Liu L; Zhao X; Huang X
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397034
[TBL] [Abstract] [Full Text] [Related]
14. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
15. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract] [Full Text] [Related]
16. 2021 WHO Classification of lung cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy of first-line treatment options beyond ret-TKIs in advanced ret-rearranged non-small cell lung cancer: A multi-center real-world study.
Ge Y; Li J; Gong W; Wang J; Wei X; Liu J; Wang S; Wang L; Sun H; Cheng Q; Sun Y; Dang Q; Sun Y; Gao A
Cancer Med; 2024 Jan; 13(2):e6960. PubMed ID: 38349001
[TBL] [Abstract] [Full Text] [Related]
18. LIBretTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?
Russo A; Muscolino P; Rolfo C
Med; 2024 Feb; 5(2):112-114. PubMed ID: 38340705
[TBL] [Abstract] [Full Text] [Related]
19. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract] [Full Text] [Related]
20. Response to immune checkpoint inhibitor combination therapy in metastatic ret-mutated lung cancer from real-world retrospective data.
Yan N; Zhang H; Shen S; Guo S; Li X
BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
[TBL] [Abstract] [Full Text] [Related]
[Next]